Bank of Montreal
TRVI icon

Bank of Montreal’s Trevi Therapeutics TRVI Stock Holding History

Bank of Montreal’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-152,300
Closed -$294K – 4186
2022
Q4 		$294K Buy
+152,300
New +$300K ﹤0.01% 2920
2020
Q2 		– Sell
-7
Closed – – 4835
2020
Q1 		$0 Buy
+7
New +$32 ﹤0.01% 4703
2019
Q4 		– Sell
-11
Closed – – 5008
2019
Q3 		$0 Sell
11
-619
-98% -$3.37K ﹤0.01% 4985
2019
Q2 		$5K Buy
+630
New +$5.42K ﹤0.01% 4680

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Bank of Montreal's TRVI Position: Q1 2023 in Review

Bank of Montreal sold out of Trevi Therapeutics (TRVI) in Q1 2023, closing a stake of 152,300 shares — an estimated $294K sold.

Bank of Montreal first reported a position in TRVI in Q2 2019 and held it in 4 quarters. The position peaked at $294K in Q4 2022. 36 funds tracked by Wall St. Rank hold TRVI as of Q1 2023.

  • Bank of Montreal reported no remaining Trevi Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Bank of Montreal sold 152,300 Trevi Therapeutics shares in Q1 2023, an estimated $294K.
  • Bank of Montreal first reported a position in Trevi Therapeutics in Q2 2019 and held it in 4 quarters.
  • Bank of Montreal's Trevi Therapeutics position peaked at $294K in Q4 2022.
  • 36 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2023.

Based on Bank of Montreal's 13F filing for Q1 2023, filed 13 Jun 2024.